News

Current applications and future outlook on integrating robotic technology in the operating room.

Real-time data analysis and intelligent automation help streamline key steps.

Robotic laser arcuate incisions reduce variability and residual astigmatism.

Neurotech Pharmaceuticals announced the first commercial manufacturing, shipment, and surgical procedure of ENCELTO, the first and only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2.

Neurotech Pharmaceuticals performs the first ENCELTO procedure.

REGENXBIO initiates a pivotal trial for surabgene lomparvovec, aiming to transform diabetic retinopathy treatment and improve patient outcomes.

Sandoz will hold exclusive or semi-exclusive marketing rights in several European and Asian countries

New research findings reveal that increased physical activity significantly slows visual field loss in patients with glaucoma, highlighting exercise as a potential protective factor.

AAVB-039 is the company’s gene therapy program for Stargardt disease secondary to biallelic mutation in ABCA4.

Ocular salvage and preservation of vision are essentially dependent on early diagnosis, and several studies have been conducted to identify the factors leading to delayed diagnosis at presentation.

An ophthalmologic examination revealed bilateral anterior uveitis, though the patient had no ocular complaints at presentation

João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases

Tirzepatide and semaglutide show favorable ocular safety compared to traditional weight loss formulations

NICE approves idebenone for Leber hereditary optic neuropathy, offering hope for vision restoration and improved quality of life for patients.

Catch up on this week's highlights in retina.

In a press release, the National Institute for Health and Care Excellence announced the first-ever approval for a mitochondrial disease treatment.

Franklin shares how methotrexate significantly reduces reoperation rates in diabetic patients with retinal detachments, enhancing postoperative outcomes and vision.

4D Molecular Therapeutics showcases promising SPECTRA trial results for 4D-150, highlighting its potential to revolutionize diabetic macular edema treatment.

The transaction is anticipated to close in 6 to 12 months subject to customary closing conditions and regulatory approval

New findings confirm TearCare's long-term effectiveness for dry eye disease, showing significant patient improvements with minimal treatments over 2 years.